The Berkeley-based biotech company announced on Tuesday that it would wind down operations, lay off staff and explore strategic alternatives, according to a press release.
The decision means that development of two allogeneic CAR-T therapies will be discontinued. Its most advanced candidate, vispa-cel, is being developed for advanced B-cell non-Hodgkin lymphoma and was approaching its next major clinical trial. But the money ran out.
BREAKING